AN OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE IN COMBINATION WITH

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。评估恩曲他滨作为治疗儿童患者艾滋病毒感染的方法是必要的，以开发新的抗逆转录病毒药物，提供简单、方便的治疗方案，并产生有效和持久的反应。恩曲他滨治疗儿童艾滋病毒感染的临床开发战略是一个分两步走的过程，目的是为儿童提供剂量指南。第一步是确定血浆图谱，第二步是探索恩曲他滨与其他抗逆转录病毒药物一起使用时的长期安全性和抗逆转录病毒活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Evaluation of emtricitabine as a treatment for HIV infection in Pediatric Patients is necessary to develop new antiretroviral medications that provide simple and convenient treatment regimens with a potent and durable response. The strategy for the clinical development of emtricitabine for the treatment of HIV Infection in pediatric patients is a two-step process with the goal of providing a dosing guideline in children. The first step is to determine the plasma profiles and the second step is to explore the long-term safety and antiretroviral activity of emtricitabine when used with other antiretroviral medications.